Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-0004.2012.01861.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Construction of a prognostic model for gastric cancer based on immune infiltration and microenvironment, and exploration of MEF2C gene function.
BMC Med Genomics
January 2025
Department of Oncology, The First People's Hospital of Yibin, No.65, Wenxing Street, Cuiping District, Yibin, 644000, China.
Background: Advanced gastric cancer (GC) exhibits a high recurrence rate and a dismal prognosis. Myocyte enhancer factor 2c (MEF2C) was found to contribute to the development of various types of cancer. Therefore, our aim is to develop a prognostic model that predicts the prognosis of GC patients and initially explore the role of MEF2C in immunotherapy for GC.
View Article and Find Full Text PDFDirect cardiac reprogramming via combined CRISPRa-mediated endogenous Gata4 activation and exogenous Mef2c and Tbx5 expression.
Mol Ther Nucleic Acids
December 2024
McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Direct cardiac reprogramming of fibroblasts into induced cardiomyocytes (iCMs) can be achieved by ectopic expression of cardiac transcription factors (TFs) via viral vectors. However, risks like genomic mutations, viral toxicity, and immune response limited its clinical application. Transactivation of endogenous TFs emerges as an alternative approach that may partially mitigate some of the risks.
View Article and Find Full Text PDFPersonalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations.
JCO Precis Oncol
November 2024
Department of Hematology, Mayo Clinic, Rochester, MN.
Purpose: BRAF and MEK inhibitors are standard treatments in histiocytic disorders, such as Erdheim-Chester disease (ECD). Some patients lack MAPK-pathway alterations, making these treatments less effective.
Methods: We describe three patients with histiocytic disorders who have novel non-MAPK pathway alterations.
Detection of chromosome 5q interstitial deletion of 5q14.3-q31.1 by chromosome microarray analysis in a second-trimester fetus with multiple congenital anomalies and a literature review of chromosome 5q interstitial deletion syndrome.
Taiwan J Obstet Gynecol
November 2024
Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan.
Article Synopsis
- - A 30-year-old woman underwent prenatal ultrasound at 14 weeks and was found to be carrying a fetus with multiple congenital anomalies, prompting chromosome microarray analysis (CMA) after the pregnancy was terminated.
- - The analysis revealed a significant deletion on chromosome 5 (5q14.3-q31.1), affecting numerous genes, including NR2F1 and MEF2C, indicating a genetic basis for the fetal conditions observed.
- - CMA proves to be an effective tool in identifying genetic abnormalities in fetuses with unexplained congenital anomalies, highlighting its value in prenatal genetic testing.
MEF2C is a Potential Prognostic Biomarker and is Correlated with Immune Infiltrates in Lung Adenocarcinoma.
Curr Med Chem
October 2024
The First Clinical Medical School, Jinan University, Guangzhou, 510630, Guangdong, China.
Article Synopsis
- This study investigates the role of Myocyte Enhancer Factor 2 C (MEF2C) in lung adenocarcinoma (LUAD) using bioinformatics and experimental methods to find its potential as a diagnostic marker.
- Results show that lower MEF2C levels in LUAD patients correlate with less effective treatment outcomes, gender differences, and reduced overall survival, making MEF2C a significant prognostic factor.
- MEF2C is involved in various biological processes and shows connections to immune system interactions and drug sensitivities, indicating its complex role in cancer biology.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!